Fed. Circ. OKs Ax Of Lilly's Axiron Patent, Allows Generics
The Federal Circuit ruled Wednesday that a key claim of an Eli Lilly & Co. patent on the testosterone drug Axiron is invalid, upholding a lower court ruling that spurred the...To view the full article, register now.
Already a subscriber? Click here to view full article